# Olive Leaf Extracts in the Control of Cardiovascular Risk

Study · id `cardio:ct-nct05297110` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05297110](<https://clinicaltrials.gov/study/NCT05297110>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05297110

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT05297110. Randomized; single masking; primary purpose prevention. Start 2021-08-01 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT05297110, source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)
- Started: 2021-08-01 (actual) (ClinicalTrials.gov record NCT05297110, source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)
- Primary completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT05297110, source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)
- Completion: 2023-12-01 (anticipated) (ClinicalTrials.gov record NCT05297110, source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)
- Countries: Tunisia (ClinicalTrials.gov record NCT05297110, source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05297110-2023-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Olive Leaf Extracts in the Control of Cardiovascular Risk
- Acronym: Atherolive
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension
- Intervention (Drug): atherolive
- Lead sponsor: University of Monastir
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Monastir (`cardio:org-university-of-monastir`)

## Provenance

Content hash: 60ddd36fb8b82c9dab8870c2925bb40169ff93668fff73f608503e0e88c474ff
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
